InSitu Biologics has made considerable progress executing our business plan over the past several months, even in the midst of ongoing COVID-19 challenges.  We recently raised over $2 million in a convertible note financing round, received a pre-investigational new drug application response from the FDA, and made significant improvements to our drug formulation.

For additional information regarding our progress, please take some time to read our company update.


Shareholder Update_July 2020_Final

(click here to read)